The Motley Fool
SGYP Could Soon Rocket Higher
Key phase 3 catalyst is approaching for SGYP
Wall Street Journal
Fitbit Isn’t Too Stretched
Fitbit’s valuation leaves the stock some room to run, even after scoring a nice IPO pop.
By Dan Gallagher
June 1823 2015
The company, on July 01, 2015, reported that it has appointed Timothy Callahan and Richard Daly as new independent directors to its board. Both Mr. Callahan and Mr. Daly have direct experience in primary care and gastrointestinal markets and have led large organizational change and successful business growth, in a variety of areas, including all aspects of commercial, acquisitions, partnerships and product launches.
Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization.
Effects of AQX-1125 observed on the primary end point of reduction in pain together with several statistically significant secondary endpoints, underscore the potential of AQX-1125 as a once-daily, oral therapy for this debilitating disease.
Aveo’s final results have nowindicated that there is a median PFS in this setting of 11.0 months. Even better, the median overall survival was 21.6 months.
will same the samw